Are Peptides Legal? What FDA’s 2026 Lists Say

Some peptides are legal prescription drugs, and most of the ones sold online are not. Semaglutide, the drug in Wegovy and Ozempic, is an FDA-approved peptide drug. BPC-157, TB-500, MOTS-c and most other “research peptides” are not approved for anything, are not on the list of substances a US pharmacy may use to compound. FDA’s April 2026 update lists them as “withdrawn” from its safety-risk category, and that did not make them legal to compound. Here is what each FDA list actually says, peptide by peptide.

Three different questions hide inside “is it legal?”

Sellers and critics both blur these together, so it helps to pull them apart.

1. Is it an FDA-approved drug? If yes, a doctor can prescribe the approved product and a pharmacy can dispense it. Semaglutide (Wegovy, Ozempic, Rybelsus) is in this group.^[15][16] BPC-157 and TB-500 are not.
2. May a pharmacy compound it? A compounding pharmacy mixes a drug for one patient from raw ingredients. Federal law limits which raw ingredients it may use, and most research peptides fall outside those limits.^[1]
3. Does a “research use only” label change anything? For a seller whose website shows the product is meant for people, FDA says no.^[13]

The lists that decide what a pharmacy may compound

Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound only from ingredients that meet one of three tests: the ingredient has a USP or NF monograph, it is already an ingredient in an approved drug, or it appears on FDA’s 503A bulks list.^[1] A 503A pharmacy also needs a prescription written for one specific patient.^[5]

The 503A bulks list is short. It names six substances, among them Brilliant Blue G and cantharidin for topical use. None is a peptide.^[4] While FDA works through nominations for that list, an interim policy sorts nominated substances into three categories:^[1]

Two details matter for peptide buyers. First, FDA says it does not intend to place substances nominated on or after January 7, 2025 into any of these categories, so a newly nominated peptide gets no interim cover.^[1] Second, a substance that is on none of these lists and meets none of the three tests has no 503A route at all.

Outsourcing facilities, regulated under section 503B, are a separate channel. They follow manufacturing-quality (CGMP) rules and are inspected by FDA on a risk-based schedule.^[5] FDA’s safety-risk list marks each entry as 503A, 503B or both, which is why a peptide can be restricted in one channel and not named in the other.^[3]

What the April 2026 update shows, and why it is not a green light

FDA’s page on bulk substances that may present significant safety risks, current as of April 22, 2026, now has two tables. The first is the active Category 2 list. The second is headed “Bulk drug substances nominated but withdrawn”, which FDA describes as substances “previously in category 2” that “were withdrawn by the nominators.”^[3]

Most of the peptides sold online now sit in that second table: BPC-157, TB-500 (listed as thymosin beta-4 fragment), MOTs-C, KPV, CJC-1295, epitalon, Semax, selank, emideltide (DSIP), thymosin alpha-1, cathelicidin LL-37, Melanotan II, AOD-9604, PEG-MGF, dihexa acetate and injectable GHK-Cu.^[3] FDA kept its safety notes for each. For CJC-1295, FDA points to serious adverse events, among them a faster heart rate and a vasodilatory reaction. For Melanotan II, it cites published case reports of “melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”^[3]

Several of these peptides were then put back in front of FDA’s Pharmacy Compounding Advisory Committee, which advises the agency.^[5] Its July 23 and 24, 2026 meeting took up BPC-157, KPV, TB-500 and MOTs-C on the first day and emideltide, Semax and epitalon on the second, each as a candidate for the 503A bulks list.^[6] FDA’s own briefing documents for BPC-157, TB-500, MOTS-c and KPV each conclude that “a balancing of the criteria weighs against” adding them.^{[7][8][9][10]} Those documents also say FDA “will not issue a final determination” until it has considered the committee’s input. As of September 2026 the meeting page posts no vote results, and no FDA rule has added any of them to the list.^[6]

Peptide status on FDA's lists, September 2026

This table covers peptides that FDA’s lists name. A peptide missing from it is not cleared by omission; check it in our peptide status checker.

Sources for the table: FDA’s category lists (updated May 14, 2026), its safety-risk page (April 22, 2026), the 503A bulks list in 21 CFR 216.23 and the July 2026 briefing documents.^[2][3][4][7] GHK-Cu has moved twice this year. FDA removed it from Category 1 on April 22, 2026, when the nominations were withdrawn, then added the non-injectable form back after one nominator clarified on May 5 that it meant to withdraw only the injectable route. FDA says it will consult the advisory committee on GHK-Cu before the end of February 2027.^[2]

Category 1 is the only category that comes with FDA’s stated intent not to act against a compounder, and even that is conditional and interim.^[1] It is not an approval, and it says nothing about whether a product works.

What “research use only” means legally

Many peptide sites print “research use only” on the vial, or warn that the contents are not meant for people. FDA looks past the label to how the product is sold. In its December 2024 warning letter to Summit Research Peptides, FDA wrote: “Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use.”^[13] Because the products were unapproved new drugs, FDA said selling them across state lines violated the Act.^[13]

FDA’s consumer page on GLP-1 drugs says the same about that market: companies have put false research-only labels on semaglutide, tirzepatide, retatrutide and similar drugs, then sold them straight to consumers along with dosing instructions, and FDA “urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”^[14] For how this plays out with tirzepatide specifically, see buying tirzepatide as a research chemical.

Peptides that are approved drugs, and where the line sits

“Peptide” is a chemical description, not a legal status. The GLP-1 drugs are peptides: the Rybelsus label notes that semaglutide’s “peptide backbone is produced by yeast fermentation.”^[16] Wegovy, as an injection and as a tablet, is FDA-approved to reduce excess body weight in adults with obesity, or with overweight and at least one weight-related condition; the injection is also approved for children 12 and older with obesity.^[15] Those approved products are the legal way to get semaglutide.

Compounded versions are narrower than they sound. FDA says a compounded drug carries no FDA approval and gets no agency check of its safety, effectiveness or quality before sale, and that federal law bars compounders from using retatrutide or cagrilintide at all.^[14] Our guide to what cannot legally be compounded covers the GLP-1 side in detail.

Tesamorelin shows how an approval can still leave no compounding route. It is sold as Egrifta, but FDA lists it among the drug approvals that were deemed biologics licenses on March 23, 2020.^[12] From that date, FDA said, those products “will not be eligible for the exemptions for compounded drugs under sections 503A and 503B.”^[11] Brand Egrifta can be prescribed. A compounded tesamorelin has no route through either channel.

How to check a peptide seller

1. Find the peptide in the table above or in our status checker. If it is withdrawn, in Category 2 or 3, or on no list, a pharmacy has no 503A route to compound it.
2. Ask who dispenses it. A lawful compounded product comes from a named, state-licensed pharmacy or a registered outsourcing facility, on a prescription written for you. Our pharmacy verification guide shows how to check a license.
3. Read the label and the marketing together. A vial marked “research use only” next to dosing advice is the pattern FDA has cited in warning letters.^[13]
4. Check the evidence separately from the law. Legal status says nothing about whether a peptide works. Our review of which peptides have human trials covers that question, and what FDA said about BPC-157 goes deeper on the most popular one.

Each peptide guide on our peptides hub lists the telehealth sellers we track that offer it, so you can see who prescribes what before you pay.

Common questions